Opioids Market Analysis, Share, Industry, Opportunities 2031

Segments - Opioids Market by Products (Immediate-release/Short-acting [Products {Codeine, Oxycodone, Hydrocodone, Fentanyl, Morphine, Hydroxymorphone, Oxymorphone, Propoxyphene and Others}, and Applications {Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression, and De-addiction}], and Extended-release/Long-acting [Products {Oxycodone, Hydrocodone, Methadone, Fentanyl, Morphine, Oxymorphone, Tapentadol, Buprenorphine, Hydromorphone, and Others} and Applications {Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression, and De-addiction}]), Applications (Pain Relief [Cancer Pain, Postoperative Pain Management, Low-back Pain, Orthopedic, Neuropathic Pain, and Fibromyalgia], Anesthesia, Cough Suppression, Diarrhea Suppression, and De-addiction), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

Opioids Market Outlook 2031

The global opioids market size was valued at USD 4.69 Billion in 2022 and is likely reach to USD 6.23 Billion by 2031, expanding at a CAGR of 3.2% during the forecast period, 2023–2031. The growth of the market is attributed to the growing prevalence of diseases which causes chronic pain such as lower back pain, arthritis, cancer, fibromyalgia, and postsurgical pain.

The U.S. Food and Drug Administration (FDA) regulated the market because of a large number of drug-abuse deaths registered in the country. They have released precise guidelines to manufacture, store, sell, and market opioid products.

A group of narcotic pain-relieving drug is known as opioids. These drugs interact with opioid receptors in cells and activate them. Poppy plants such as morphine or synthesized in a laboratory such as fentanyl are used to make opioids. Opioids are largely used as cough suppressant, diarrhea suppressant, anesthesia, and in pain management that arises due to various diseases.

Use of opioids for longer period of time results into dependency, drug addiction and rise in drug abuse which causing in high death rates. According to the American Society of Addiction Medicine, around 18,900 deaths were reported due to drug overdose and 10,500 were died because of heroin overdose.

Seeing such a high rate of death due to opioid dependency and abuse, the U.S. government and other countries advocate against the use of opioids. Medicare, in January 2019, launched formed new opioid prescribing guidelines which affect Medicare Part D beneficiaries.

Part D plans are anticipated to control early opioid supply to a 7-day supply or less. This guideline effect to those Medicare patients who are not prescribed for use of opioid.

Medical marijuana is anticipated as the possible antidote for epidemic that led to two-thirds of deaths every year in the U.S. As per recent study, it is observed that over dose death and drug abuse from prescription painkillers are reduced in those states where marijuana is legalized.

Biopharmaceutical companies expect that medical marijuana product is projected to replace opioid use for chronic pain management.

Market Trends, Drivers, Restraints, and Opportunities

Growing demand of opioids in healthcare industries, and value oriented consumers are projected to drive the market expansion.
Growing prevalence of chronic pain and orthopedic diseases, and increasing demand of opioids drugs in diarrhea suppressant and cough suppressant are anticipated to fuel the growth of the market.
Increasing surgical procedures and road accidents, and rising palliative care facilities are propelling the market growth over the forecast period.
Increasing focus on abuse-deterrent formulation (ADF) and inclination toward extended release formulations are expected to boost the expansion of the market.
Stringent regulations, misuse of opioids, and side effects of opioids are projected to restrict the market growth.
Legalization of cannabis as an alternative to opioids is key factor that hampers the market growth over the forecast period.

Scope of Opioids Market Report

The report on the global opioids market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Opioids Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	Products (Immediate-release/Short-acting [Products {Codeine, Oxycodone, Hydrocodone, Fentanyl, Morphine, Hydroxymorphone, Oxymorphone, Propoxyphene and Others}, and Applications {Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression, and De-addiction}], and Extended-release/Long-acting [Products {Oxycodone, Hydrocodone, Methadone, Fentanyl, Morphine, Oxymorphone, Tapentadol, Buprenorphine, Hydromorphone, and Others} and Applications {Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression, and De-addiction}]), Applications (Pain Relief [Cancer Pain, Postoperative Pain Management, Low-back Pain, Orthopedic, Neuropathic Pain, and Fibromyalgia], Anesthesia, Cough Suppression, Diarrhea Suppression, and De-addiction)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	Pharma L.P., Allergan, West-Ward Pharmaceuticals Corporation, Janssen Pharmaceuticals, Inc., Pfizer, Inc., Egalet Corporation, and Sun Pharmaceutical Industries Limited

Opioids Market Segment Insights

Extended-release segment is accounted the major market share

On the basis of products, the opioids market is segmented into immediate-release (IR)/short-acting and extended-release (ER)/long-acting. The immediate-release/short-acting segment is further sub-divided into products and applications.

The IR products sub-segment is further sub-divided into codeine, oxycodone, hydrocodone, fentanyl, morphine, hydroxymorphone, oxymorphone, propoxyphene and others. The IR applications sub-segment is further sub-divided into pain relief, anesthesia, cough suppression, diarrhea suppression, and de-addiction.

The extended-release segment is accounted largest market share due to increasing use in chronic pain management. But, misuse of these drugs caused serious public health crisis.

As a result of this, the U.S. FDA, in September 2018, released its final Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) for immediate-release and extended-release opioids which helps in decreasing the rate of addiction and reducing the exposure of these drugs.

The extended-release/long-acting segment is further sub-divided into products and applications. The ER products sub-segment is further sub-divided into oxycodone, hydrocodone, methadone, fentanyl, morphine, oxymorphone, tapentadol, buprenorphine, hydromorphone, and others.

The ER applications sub-segment is further sub-divided into pain relief, anesthesia, cough suppression, diarrhea suppression, and de-addiction.

Pain relief segment is projected to hold a major market share

Based on applications, the opioids market is divided into pain relief, anesthesia, cough suppression, diarrhea suppression, and de-addiction. The pain relief segment is further sub-divided into cancer pain, postoperative pain management, low-back pain, orthopedic, neuropathic pain, and fibromyalgia.

The pain relief segment is expected to hold a key share of the market during the forecast period owing to high use of pain management therapies. On the other hand, use of products for pain is anticipated to decline in coming years due to implementation of new regulatory framework. Centers for Disease control and Prevention (CDC) has formed new guideline for prescribing opioids for chronic pain.

Based on these guidelines, for chronic pain other than palliative, end-of-life care, and active cancer the non-opioid therapy should be preferred.

Opioids Market Regional Outlook

Asia Pacific is expected to dominate the market

On the basis of regions, the opioids market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America held the largest market share during the forecast period owing to highest consumption in the region.

But, the region is witnessing a decline in market share due to increasing initiatives by government to battle the crisis in the U.S. The U.S. government, in June 2018, introduced advertising campaign to battle addiction. Also, opioid products such as Purdue Pharma’ OxyContin are discontinued in Canada and U.S.

On the other hand, the market of Asia Pacific is expected to dominate the market in the coming years due to focus shifting of companies such as Purdue Pharma towards Asia Pacific for enhancing their presence in the market.

Segments

Products

Immediate-release/Short-acting
- Products
  - Codeine
  - Oxycodone
  - Hydrocodone
  - Fentanyl
  - Morphine
  - Hydroxymorphone
  - Oxymorphone
  - Propoxyphene
  - Other IR
- Applications
  - Pain Relief
  - Anesthesia
  - Cough Suppression
  - Diarrhea Suppression
  - De-addiction
Extended-release/Long-acting
- Products
  - Oxycodone
  - Hydrocodone
  - Methadone
  - Fentanyl
  - Morphine
  - Oxymorphone
  - Tapentadol
  - Buprenorphine
  - Hydromorphone
  - Other ER
- Applications
  - Pain Relief
  - Anesthesia
  - Cough Suppression
  - Diarrhea Suppression
  - De-addiction

Applications

Pain Relief
- Cancer Pain
- Postoperative Pain Management
- Low-back Pain
- Orthopedic
- Neuropathic Pain
- Fibromyalgia
Anesthesia
Cough Suppression
Diarrhea Suppression
De-addiction

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

Pharma L.P.
Allergan
West-Ward Pharmaceuticals Corporation
Janssen Pharmaceuticals, Inc.
Pfizer, Inc.
Egalet Corporation
Sun Pharmaceutical Industries Limited

Competitive Landscape

Key players competing in the opioids market include/are Pharma L.P., Allergan, West-Ward Pharmaceuticals Corporation, Janssen Pharmaceuticals, Inc., Pfizer, Inc., Egalet Corporation, and Sun Pharmaceutical Industries Limited.

Major market players are adopting several business strategies including mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.

For instance, Purdue Pharma is increasing its presences into Middle East & Africa, Asia, and Latin America. Awareness programs are organized by the company in which doctors are advised to prescribe painkillers for helping patients to overcome opiophobia.

Opioids Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Opioids Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Opioids Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Opioids Market - Supply Chain
  4.5. Global Opioids Market Forecast
     4.5.1. Opioids Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Opioids Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Opioids Market Absolute $ Opportunity
5. Global Opioids Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Opioids Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Opioids Demand Share Forecast, 2019-2026
6. North America Opioids Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Opioids Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Opioids Demand Share Forecast, 2019-2026
7. Latin America Opioids Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Opioids Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Opioids Demand Share Forecast, 2019-2026
8. Europe Opioids Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Opioids Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Opioids Demand Share Forecast, 2019-2026
9. Asia Pacific Opioids Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Opioids Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Opioids Demand Share Forecast, 2019-2026
10. Middle East & Africa Opioids Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Opioids Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Opioids Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Opioids Market: Market Share Analysis
  11.2. Opioids Distributors and Customers
  11.3. Opioids Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Pharma L.P.
     11.4.2. Allergan
     11.4.3. West-Ward Pharmaceuticals Corporation
     11.4.4. Janssen Pharmaceuticals, Inc.
     11.4.5. Pfizer, Inc.
     11.4.6. Egalet Corporation
     11.4.7. Sun Pharmaceutical Industries Limited